VANCOUVER, British Columbia--(BUSINESS WIRE)--Medifocus, Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that it has filed on January 22, 2010, its response to two (2) remaining questions with the FDA in the United States of America (USA) to obtain clearance to initiate a pivotal phase III clinical trial using the Company’s Microfocus APA 1000 System for the treatment of breast cancer in the USA and worldwide. As stated prior, Medifocus filed its initial Investigational Device Exemption (IDE) application with the FDA on June 11, 2009. After a comprehensive review by the FDA to the Company’s application, Medifocus has been diligently corresponding with the FDA to address the twenty-one (21) initial concerns or request for additional information. Medifocus has already fully satisfied 19 of the 21 initial comments to date and has just filed its response to the remaining two comments.
